PSTX - FDA lifts clinical hold on Poseida's prostate cancer cell therapy study

Poseida Therapeutics (PSTX) jumps 15% premarket on the heels of its announcement that the FDA has removed clinical holds on Phase 1 trial of P-PSMA-101 in metastatic castration-resistant prostate cancer; the company plans to resume the trial immediately.Last month, the trial was halted after one patient died due to liver failure at day 19 post-treatment.P-PSMA-101 is an autologous CAR-T therapy.

For further details see:

FDA lifts clinical hold on Poseida's prostate cancer cell therapy study